Abood Okal

发表

A single mutant, A276S of p53, turns the switch to apoptosis.

Shams Reaz, Mohanad Mossalam, Abood Okal, 2013, Molecular pharmaceutics.

The DNA binding domain of p53 is sufficient to trigger a potent apoptotic response at the mitochondria.

Mohanad Mossalam, Abood Okal, Carol S. Lim, 2013, Molecular pharmaceutics.

Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment.

D. Pookot, Abood Okal, P. Kassner, 2019, Journal of medicinal chemistry.

Delivery of a Monomeric p53 Subdomain with Mitochondrial Targeting Signals from Pro-Apoptotic Bak or Bax

Mohanad Mossalam, Abood Okal, Carol S. Lim, 2014, Pharmaceutical Research.

Direct induction of apoptosis using an optimal mitochondrially targeted p53.

Mohanad Mossalam, Abood Okal, Carol S. Lim, 2012, Molecular pharmaceutics.

Cancer Biology: Some Causes for a Variety of Different Diseases

Shams Reaz, Abood Okal, Carol S. Lim, 2013 .

Re-engineered p53 Activates Apoptosis In Vivo and Causes Primary Tumor Regression in A Dominant Negative Breast Cancer Xenograft Model

M. Salama, Abood Okal, Carol S. Lim, 2014, Gene Therapy.

Re-Engineered p53 Chimera with Enhanced Homo-Oligomerization That Maintains Tumor Suppressor Activity

T. Cheatham, Abood Okal, Carol S. Lim, 2014, Molecular pharmaceutics.

A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells.

Andrew S. Dixon, Mohanad Mossalam, Abood Okal, 2013, Molecular pharmaceutics.

Abstract 1176: Bypassing the dominant-negative effect of mutant p53 in cancer cells

Mohanad Mossalam, Abood Okal, Carol S. Lim, 2012 .

Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment.

Abood Okal, P. Kassner, G. Cutler, 2019, Journal of medicinal chemistry.